DOC

Meningococcal C Conjugate Vaccine (MenCCV)

By Lorraine Barnes,2014-05-12 07:14
5 views 0
Meningococcal C Conjugate Vaccine (MenCCV)

    MODEL STANDING DRUG ORDER

    Title Meningococcal C Conjugate Vaccine (MenCCV)

    NeisVac-C?

    Location www.health.sa.gov.au/pehs/immunisation-index.htm

    Date Reviewed 1 September 2011

    Next Due Date for 31 August 2013

    Review

    Author Immunisation Section (IS)

    Person Responsible Maureen Watson

    Position Nursing Director, IS

    1References 1. NHMRC The Australian Immunisation Handbook 9th Edition 2008

    2. Monthly Index for Medical Specialties (MIMS)

    33. Product Information as licensed by the Therapeutic Goods Administration (Australia)

    4. Health Practitioner Regulation National Law (SA) Act 2010

    5. Controlled Substances Act 1984 (and its Regulations)

    6. Consent to Medical Treatment and Palliative Care Act 1995

    7. Australian Nursing and Midwifery Council (ANMC) National Competency Standards

    APPLICATION OF MODEL STANDING DRUG ORDER 1. Clinical practice Any immunisation service conducted by a Medical Practice, Local Government, Community

    areas where SDO Health Centre, Hospital, Aboriginal Health Service, Royal Flying Doctor Service or any other

    can be used health service

    ENDORSEMENT COMMITTEE MEDICAL OFFICER, SENIOR NURSE AND MANAGEMENT

    Name Signature: _______________________ Title: ________________________________________ Date: ______________ Name Signature: _______________________ Title: ________________________________________ Date: ______________ Name Signature: _______________________ Title: ________________________________________ Date: ______________

     Page 1 of 6 July 2011

    Meningococcal C Conjugate Vaccine ~ MODEL SDO

    AUTHORISATION

    This Standing Drug Order authorises appropriately qualified staff that have read and understood the following information

    to administer NeisVac-C vaccine to eligible individuals

    STAFF AUTHORISATION

    2. Staff credentialing 2.1 Registered Nurse or Midwife

    requirements 2.1.1 Accountable and responsible for own actions within nursing practice in accordance

    with the Australian Nursing and Midwifery Council (ANMC) 2006 National Competency

    Standards

    2.1.2 Practices in accordance with Division 8, Subdivision 1, section 94 (1) Health

    Practitioner Regulation National Law (SA) Act 2010

    2.1.3 Current Certificate of Registration with the Nursing and Midwifery Board of Australia

    2.1.4 Certificate in Cardio Pulmonary Resuscitation (CPR) within the last 12 months

    2.2 Enrolled Nurse

     Can immunise if can demonstrate all of the following:

    2.2.1 Competence to practice and is responsible for own actions in accordance with ANMC

    Competency Standards

    2.2.2 Compliance with organisational standards, policies and procedures

    2.2.3 Compliance with all relevant legislation and guidelines

    2.2.4 Practices in accordance with Division 8, Subdivision 1, section 94 (1) Health

    Practitioner Regulation National Law (SA) Act 2010

    2.2.5 Assessment of the client by Registered Nurse/Midwife or Medical Practitioner prior to

    vaccination

    2.2.6 Direct or indirect supervision by a Registered Nurse or Midwife

    2.2.7 Current Certificate of Enrolment with the Nursing and Midwifery Board of Australia

    2.2.8 Certificate in CPR within the last 12 months

    2.3 Aboriginal Health Worker

    C Can immunise if they can demonstrate all of the following:

    2.3.1 Have received delegation from a Registered Nurse/Midwife

    2.3.2 Competence to practice in accordance with ANMC Competency Standards

    2.3.3 Compliance with organisational standards, policies and procedures

    2.3.4 Compliance with all relevant legislation and guidelines

    2.3.5 Assessment of the client by a Registered Nurse/Midwife prior to vaccination

    2.3.6 Direct supervision by a Registered Nurse/Midwife

    2.3.7 Certificate in CPR within the last 12 months

     Page 2 of 6 July 2011

    Meningococcal C Conjugate Vaccine ~ MODEL SDO

    NeisVac C ~ MODEL STANDING DRUG ORDER

    3. Background 3.1 This model Standing Drug Order (SDO) will not meet the need of all cases and must

    1always be used in conjunction with the current Australian Immunisation Handbook

    3.2 Clinical assessment and advice from a Medical Practitioner should be sought if the

    recommendations for a specific clinical situation cannot be determined using the SDO

    1together with the Immunisation Handbook

    4. Purpose and 4.1 To ensure the correct and controlled administration of NeisVac-C? vaccine by a person

    scope authorised according to the criteria in this SDO

    5.1 NOT to be mixed with other vaccines in the same syringe 5. Precautions

    5.2 NOT to be administered intravenously

    35.3 Use with caution in subjects with thrombocytopenia or other bleeding disorder

    6. Indications for Active immunisation of children from 6 weeks of age, adolescents and adults for protection

    use and dosage against invasive disease caused by Neisseria meningitidis serogroup C.

    6.1 A single dose of Neisvac-C is recommended for:

    - All children at 12 months of age

    - Close contacts of meningococcal disease cases due to serogroup C >2 months of

    age, not previously vaccinated

    - Laboratory personnel who frequently handle Neisseria meningitidis

    - Those >6 weeks of age with inherited defects of properdin or complement, or

    1 functional or anatomical asplenia. Refer to Immunisation Handbookp. 218.

    - All children as soon as possible when the dose of has been missed at 12 months of

    age

    - All children who have received the compressed 2, 3, 4 month schedule offered in the

    UK as a booster dose at 12 months of age or thereafter.

    6.2 No booster dose is required for children vaccinated at 2, 4 and 6 months of age in

    Australia using privately purchased vaccine

    7. Limitations 7.1 Not for use in infants aged less than 6 weeks

    7.2 Persons with immunodeficiency or those receiving immunosuppressive therapy may

    3develop lower levels of protection

    8. Relevance to 8.1 NeisVac-C? can be safely administered with the other recommended vaccines at 12

    other SDO’s months of age (refer to relevant SDOs)

    8.2 Adrenaline must always be readily available. Refer to the Adrenaline SDO

    9. Contra-indications 9.1 Anaphylaxis following previous dose of the vaccine; or

    9.2 Anaphylaxis following any component of the vaccine

    10. Presentation 10.1 NeisVac C? is presented as a single dose (0.5 mL) semi opaque to off white suspension

    in a pre-filled syringe.

     Upon storage a white deposit and clear supernatant can be observed.

    11. Procedure 11.1 Pre-immunisation

    11.1.1 Obtain a detailed immunisation history. Refer to records of vaccinations in the

    personal health record or other immunisation record card/book or on the Australian

     Page 3 of 6 July 2011

    Meningococcal C Conjugate Vaccine ~ MODEL SDO

    Childhood Immunisation Register (ACIR)

    111.1.2 Refer to the relevant sections in the Immunisation Handbook for guidelines for pre-

    vaccination assessment including the Pre-vaccination Checklist and the

    Comparison of Effects of Disease and the Side Effects of Vaccines.

    11.2 Preparation of NeisVac-C?

     11.2.1 Check the batch number and expiry date.

     11.2.2 Before use shake the prefilled syringe to obtain a homogenous white suspension

     11.2.3 Administer the vaccine immediately.

    11.3 Method of Administration for NeisVac-C?

    1 11.3.1 Administer by intramuscular injection; refer to the Handbook for recommendations

    regarding multiple injections at one visit and selection of needle gauge and length

    12. Site 12.1 Infants aged <12 months

    considerations Administer into the anterolateral thigh

    12.2 Individuals aged 12 months or over

    Administer by intramuscular injection into the deltoid muscle (preferred site). However, if

    multiple injections are required, the anterolateral thigh can be used

    13. Documentation 13.1 Record in the vaccine recipient’s personal health record or other immunisation

    record card/book and in your clinical record/data:

    13.1.1 valid consent obtained;

    13.1.2 vaccine name, brand, dose number, batch number; route and site of administration;

    13.1.3 date of administration;

    13.1.4 name and organisation of the person administering the vaccine; and

    13.1.5 date the vaccine is next due (if applicable).

    13.2 Report the vaccination of children aged less than 7 years to the ACIR Information

    line, free call 1800 653 809

    13.2.1 Ensure Indigenous identification is documented

    14. Monitoring 14.1 Observation post-vaccination

    requirements 14.1.1 Vaccine recipients should remain in the vicinity for a minimum of 15 minutes for

    observation for potential life-threatening adverse events. Adults should be warned of

    the risks of driving or operating machinery for at least 30 minutes after vaccination.

    14.2 Post-vaccination advice

    14.2.1 Give verbal and written information about common adverse events. Resources

    available include the Immunisation Consent Resource, Adverse Events

    1Following Immunisations (available on front cover inside flap of Handbook), and a

    Vaccine Safety leaflet (available from IS)

    15. Side Effects 15.1 Common:

    ; Pain, redness and swelling at injection site,

    ; mild fever

    ; irritable or unsettled

     Page 4 of 6 July 2011

    Meningococcal C Conjugate Vaccine ~ MODEL SDO

    ; decreased appetite

    15.2 Very rare:

     Severe allergic reaction (anaphylaxis), convulsions (includes possible febrile convulsions)

    116. Management of 16.1 Refer to the Immunisation Handbook for the management of an immediate adverse event Adverse Events (such as anaphylaxis) or vasovagal episode (faint)

    Following 16.2 Reporting an AEFI

    Immunisation 16.2.1 AEFI reporting form can be obtained at www.health.sa.gov.au/pehs/ (AEFI) 16.2.2 Report any serious or unexpected AEFI to the Immunisation Section by phone 1300

    232 272 or Fax: 08 8226 7197 or Post: PO Box 6, Rundle Mall, Adelaide, SA 5000

    oo 17. Storage 17.1 Store between +2C and +8C. Do not freeze.

    18. Variations from 18.1 Refer to page 222 of the Immunisation Handbook.

    Product

    Information

     Page 5 of 6 July 2011

    Meningococcal C Conjugate Vaccine ~ MODEL SDO

NURSES PROVIDING THE IMMUNISATION SERVICE

    I have read and understand the recommendations of the Standing Drug Orders. I accept that I will administer these vaccines under the described procedure in this Standing Drug Order.

    Signature: ______________________________ Printed name: _________________________________ Date: ______________

    Signature: ______________________________ Printed name: _________________________________ Date: ______________

    Signature: ______________________________ Printed name: _________________________________ Date: ______________

    Signature: ______________________________ Printed name: _________________________________ Date: ______________

    Signature: ______________________________ Printed name: _________________________________ Date: ______________ Signature: ______________________________ Printed name: _________________________________ Date: ______________ Signature: ______________________________ Printed name: _________________________________ Date: ______________

    Signature: ______________________________ Printed name: _________________________________ Date: ______________

    Signature: ______________________________ Printed name: _________________________________ Date: ______________

    Signature: ______________________________ Printed name: _________________________________ Date: ______________

    Signature: ______________________________ Printed name: _________________________________ Date: ______________ Signature: ______________________________ Printed name: _________________________________ Date: ______________

     Page 6 of 6 July 2011

Report this document

For any questions or suggestions please email
cust-service@docsford.com